Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics
|
December 1, 2012
Translational PK-PD modeling in pain
Ashraf Yassen, Paul Passier, Yasuhisa Furuichi, et al.
Pain Medicine (Malden, Mass.)
|
December 12, 2017
A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects
Klaus Schaffler, Ashraf Yassen, Peter Reeh, et al.
Journal of Pain Research
|
April 27, 2012
Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups
Christian Martini, Ashraf Yassen, Erik Olofsen, et al.
Pain Medicine (Malden, Mass.)
|
January 30, 2018
A Phase I, Randomized, Double-Blind, Laser-Evoked Potential Study to Evaluate the Analgesic/Antihyperalgesic Effect of ASP9226, a State-Dependent N-Type Voltage-Gated Calcium Channel Inhibitor, in Healthy Male Subjects
Klaus Schaffler, Weizhong He, Paul Passier, et al.
Clinical Pharmacology in Drug Development
|
February 8, 2019
A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels
Nicoline Treijtel, Christiane Collins, Michel van Bruijnsvoort, et al.
Clinical Pharmacology and Therapeutics
|
March 31, 2022
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
Claudia Meyer, Ines Dierick, Glenn Gauderat, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
September 16, 2018
Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale
Peter L Bonate, Tianli Wang, Paul Passier, et al.
Journal of Pediatric Urology
|
December 3, 2019
The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation
Søren Rittig, Małgorzata Baka-Ostrowska, Camilla Tøndel, et al.
Biopharmaceutics & Drug Disposition
|
March 4, 2011
Sugammadex is cleared rapidly and primarily unchanged via renal excretion
Pierre Peeters, Paul Passier, Jean Smeets, et al.
Clinical Pharmacology in Drug Development
|
December 3, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip
Ellen van der Aar, Henri Deckx, Sonia Dupont, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Journal of Pharmacokinetics and Pharmacodynamics
|
December 1, 2012
Translational PK-PD modeling in pain
Ashraf Yassen, Paul Passier, Yasuhisa Furuichi, et al.
Pain Medicine (Malden, Mass.)
|
December 12, 2017
A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects
Klaus Schaffler, Ashraf Yassen, Peter Reeh, et al.
Journal of Pain Research
|
April 27, 2012
Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups
Christian Martini, Ashraf Yassen, Erik Olofsen, et al.
Pain Medicine (Malden, Mass.)
|
January 30, 2018
A Phase I, Randomized, Double-Blind, Laser-Evoked Potential Study to Evaluate the Analgesic/Antihyperalgesic Effect of ASP9226, a State-Dependent N-Type Voltage-Gated Calcium Channel Inhibitor, in Healthy Male Subjects
Klaus Schaffler, Weizhong He, Paul Passier, et al.
Clinical Pharmacology in Drug Development
|
February 8, 2019
A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels
Nicoline Treijtel, Christiane Collins, Michel van Bruijnsvoort, et al.
Clinical Pharmacology and Therapeutics
|
March 31, 2022
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
Claudia Meyer, Ines Dierick, Glenn Gauderat, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
September 16, 2018
Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale
Peter L Bonate, Tianli Wang, Paul Passier, et al.
Journal of Pediatric Urology
|
December 3, 2019
The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation
Søren Rittig, Małgorzata Baka-Ostrowska, Camilla Tøndel, et al.
Biopharmaceutics & Drug Disposition
|
March 4, 2011
Sugammadex is cleared rapidly and primarily unchanged via renal excretion
Pierre Peeters, Paul Passier, Jean Smeets, et al.
Clinical Pharmacology in Drug Development
|
December 3, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip
Ellen van der Aar, Henri Deckx, Sonia Dupont, et al.
Page
of 2